Open in web browser

You are subscribed to the FormularyWatch eNews.

FormularyWatch

Share

eNews Subscribe

More Subscriptions

FORMULARY WATCH

FDA actions

FDA approves OxyContin for some pediatric patients

By Christine Blank
FDA recently granted special approval of pediatric use of OxyContin in patients aged 11 to 16 years, under specific conditions. What's behind the FDA's decision

FDA approves new Onsolis formulation

By Erin Bastick
FDA has approved a supplemental New Drug Application for a new formulation of fentanyl buccal soluble film (Onsolis, BioDelivery Sciences International) CII for the management of breakthrough pain in patients with cancer who are opioid tolerant. Side effect list

CONTINUING EDUCATION

Primer on inhalers and nebulizers

This month's CE activity is part of the CPE series, Medication Therapy Management for the Patient with Respiratory Disease. From April 2015 through December 2015, pharmacists can earn up to 18 hours of CPE credit with 9 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to discuss the various types of inhaled devices and educate pharmacists on the techniques for correct device use.

To read and print the article with TEST QUESTIONS, click here.

To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the session code 15DT33-FTX29.

The login to the Online CE Center is
https://web2.uconn.edu/pharmacyce/login.php.
All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to
https://web2.uconn.edu/pharmacyce/program_register.php.
For a full list of courses, go to
http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce

EDITOR'S PICK

6 reasons cholesterol drug guidelines must change

By Christine Blank
In a commentary published online first August 10 in the Journal of the American Medical Association (JAMA), experts from CVS Health Research Institute encouraged the cardiology community to review and reconsider current treatment guidelines for the management of high cholesterol. Get the 6 reasons

August 19, 2015

Related Articles

Drop in opioid Rx, overdoses linked to pharmacy changes

Patient-controlled pain drug device approved by FDA

Resources

Get the latest FormularyWatch updates on drug approvals, current studies, and other findings.

Click for the latest Clinical News

Click here to contact Editorial. Sales, Reprints, Classified questions? Click here to contact the Sales Team.

ModernMedicine logo
UBM  logo

UBM MEDICA